Additional file 1 of Differences in oxylipin profile in psoriasis versus psoriatic arthritis

Additional file 1: Supplementary Figure 1. Oxylipin synthesis pathways. Oxylipin synthesis from n3 and n6 precursors and the enzymes involved in their synthesis are shown. Pro-inflammatory oxylipins are marked in red, while anti-inflammatory ones are marked in blue. The precursor n3-PUFAs are marked in blue, while the n6-PUFAs are marked in red. Supplementary Figure 2. Spearman correlation between oxylipins concentrations in A) PsA and B) PsO patients. Supplementary Figure 3. Pro- and anti-inflammatory eicosanoids associated with BSA. Logistic regression was performed between each eicosanoid (pmol/ml) in patients with BSA ≤ 3 compared with patients with BSA > 3. A) Pro-inflammatory eicosanoids with p value < 0.1 after adjusting for BMI, DAS28-CRP, NSAIDs and biological therapy. B) Anti-inflammatory eicosanoids with p value < 0.1 after adjusting for BMI, DAS28-CRP, NSAIDs and biological therapy. Other factors, including comorbidities, gender and age were not found to influence eicosanoid levels and were not included in the model. C) Significant eicosanoids (p < 0.1) are circled in green if upregulated in patients with BSA > 3, and in red if downregulated in these patients. BMI body mass index, DAS28-CRP: disease activity score using the 28 joint count and C reactive protein; NSAIDs: non-steroidal anti-inflammatory drugs.